CTGO vs MNPR Comparison

Contango Silver & Gold Inc, formerly Contango Ore Inc operates in the United States. The company is engaged in the exploration for and development of gold ore and associated minerals in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin, whose governmental entity is the Tetlin Tribal Council, for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.